Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.15 AUD 0.33% Market Closed
Market Cap: 608.2m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Clinuvel Pharmaceuticals Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clinuvel Pharmaceuticals Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Total Current Liabilities
AU$25.2m
CAGR 3-Years
43%
CAGR 5-Years
38%
CAGR 10-Years
31%
Immutep Ltd
ASX:IMM
Total Current Liabilities
AU$10.5m
CAGR 3-Years
25%
CAGR 5-Years
15%
CAGR 10-Years
14%
Mesoblast Ltd
ASX:MSB
Total Current Liabilities
$73.2m
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Total Current Liabilities
$5B
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
19%
Telix Pharmaceuticals Ltd
ASX:TLX
Total Current Liabilities
AU$165.1m
CAGR 3-Years
102%
CAGR 5-Years
82%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Total Current Liabilities
AU$9.1m
CAGR 3-Years
40%
CAGR 5-Years
87%
CAGR 10-Years
28%
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
608.4m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
20.89 AUD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's Total Current Liabilities?
Total Current Liabilities
25.2m AUD

Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's Total Current Liabilities amounts to 25.2m AUD.

What is Clinuvel Pharmaceuticals Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
31%

Over the last year, the Total Current Liabilities growth was -1%. The average annual Total Current Liabilities growth rates for Clinuvel Pharmaceuticals Ltd have been 43% over the past three years , 38% over the past five years , and 31% over the past ten years .

Back to Top